O-23 METABOLIC ASSOCIATED FATTY LIVER DISEASE CLINICAL PROFILE IN LEAN PATIENTS: CAN IT BE DIFFERENT?
Background: The prevalence of metabolic associated fatty liver disease (MAFLD) in lean patients has grown around the world and the better understanding of this liver disease, in these individuals, has become of interest. Aim: To evaluate the profile of MAFLD in lean compared to obese patients. Metho...
Main Authors: | , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2021-09-01
|
Series: | Annals of Hepatology |
Online Access: | http://www.sciencedirect.com/science/article/pii/S166526812100209X |
id |
doaj-6c1937db8091499e949ceb0941516cd9 |
---|---|
record_format |
Article |
spelling |
doaj-6c1937db8091499e949ceb0941516cd92021-09-29T04:24:24ZengElsevierAnnals of Hepatology1665-26812021-09-0124100510O-23 METABOLIC ASSOCIATED FATTY LIVER DISEASE CLINICAL PROFILE IN LEAN PATIENTS: CAN IT BE DIFFERENT?Andreza Rosa Cabral0Ana Rafaela S. Do Vale1Naiades S. Almeida2Raquel Rocha3Antonio Ricardo C.F. de Andrade4Ana Cristina Landin5Helma P. Cotrim6Nonalcoholic Steatohepatitis Study Group - Medicine School – Federal University of Bahia (UFBA) – Brazilian Research Council (CNPQ) - BrazilNonalcoholic Steatohepatitis Study Group - Medicine School – Federal University of Bahia (UFBA) – Brazilian Research Council (CNPQ) - BrazilNonalcoholic Steatohepatitis Study Group - Medicine School – Federal University of Bahia (UFBA) – Brazilian Research Council (CNPQ) - BrazilNonalcoholic Steatohepatitis Study Group - Medicine School – Federal University of Bahia (UFBA) – Brazilian Research Council (CNPQ) - BrazilNonalcoholic Steatohepatitis Study Group - Medicine School – Federal University of Bahia (UFBA) – Brazilian Research Council (CNPQ) - BrazilNonalcoholic Steatohepatitis Study Group - Medicine School – Federal University of Bahia (UFBA) – Brazilian Research Council (CNPQ) - BrazilNonalcoholic Steatohepatitis Study Group - Medicine School – Federal University of Bahia (UFBA) – Brazilian Research Council (CNPQ) - BrazilBackground: The prevalence of metabolic associated fatty liver disease (MAFLD) in lean patients has grown around the world and the better understanding of this liver disease, in these individuals, has become of interest. Aim: To evaluate the profile of MAFLD in lean compared to obese patients. Methodology: This case-series included patients with MAFLD from a hepatology clinic. MAFLD criteria included the presence of steatosis (ultrasound) and one of the following clinical conditions: overweight/obesity, type 2 diabetes mellitus (T2DM), other features of metabolic dysfunction. Fibrosis was evaluated by FIB4 and APRI scores. Two groups were considered: G1-lean adult (BMI≤24.99 kg/m²); elderly (≥60 years- BMI<28 kg/m²) patients; G2-obese adult (BMI≥25kg/m²); elderly (BMI>28kg/m²). SPSS software was used for data analysis. Results: A total of 135 MAFLD patients were included: 57(42.2%) in G1; 78(57.8%) in G2. G1 characteristics: Mean age was 62.26 years (SD=11.71); 70.2% were women; 75% were of African descent (self-declared); BMI mean: 24.59kg/m²(SD=2.37). Hypertriglyceridemia (HYT) was observed in 42.9% patients, T2DM in 47.4%, arterial hypertension (AH) in 54.4%, and low HDL 41.2%. Fibrosis not observed by FIB4 or APRI in all lean cases. G2 characteristics: Mean age was 55.62 years (SD=10.4); 80.8% were women; BMI mean: 32.05kg/m² (SD=3.78); 91% were of African descent. AH was found in 57.7% of the cases; T2DM in 46.2%; HYT in 36.1% and low HDL in 38.6%. Fibrosis was not observed by FIB4 and 5.5% presented fibrosis by APRI. Conclusions: In these lean patients, MAFLD was frequent in elderly women; hypertriglyceridemia, T2DM were relevant risk factor; and they did not present fibrosis by noninvasive scores. The prevalence of Afro descent in this MAFLD population was elevated and the ethnicity influence in these cases needs to be better understood in future studies.http://www.sciencedirect.com/science/article/pii/S166526812100209X |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Andreza Rosa Cabral Ana Rafaela S. Do Vale Naiades S. Almeida Raquel Rocha Antonio Ricardo C.F. de Andrade Ana Cristina Landin Helma P. Cotrim |
spellingShingle |
Andreza Rosa Cabral Ana Rafaela S. Do Vale Naiades S. Almeida Raquel Rocha Antonio Ricardo C.F. de Andrade Ana Cristina Landin Helma P. Cotrim O-23 METABOLIC ASSOCIATED FATTY LIVER DISEASE CLINICAL PROFILE IN LEAN PATIENTS: CAN IT BE DIFFERENT? Annals of Hepatology |
author_facet |
Andreza Rosa Cabral Ana Rafaela S. Do Vale Naiades S. Almeida Raquel Rocha Antonio Ricardo C.F. de Andrade Ana Cristina Landin Helma P. Cotrim |
author_sort |
Andreza Rosa Cabral |
title |
O-23 METABOLIC ASSOCIATED FATTY LIVER DISEASE CLINICAL PROFILE IN LEAN PATIENTS: CAN IT BE DIFFERENT? |
title_short |
O-23 METABOLIC ASSOCIATED FATTY LIVER DISEASE CLINICAL PROFILE IN LEAN PATIENTS: CAN IT BE DIFFERENT? |
title_full |
O-23 METABOLIC ASSOCIATED FATTY LIVER DISEASE CLINICAL PROFILE IN LEAN PATIENTS: CAN IT BE DIFFERENT? |
title_fullStr |
O-23 METABOLIC ASSOCIATED FATTY LIVER DISEASE CLINICAL PROFILE IN LEAN PATIENTS: CAN IT BE DIFFERENT? |
title_full_unstemmed |
O-23 METABOLIC ASSOCIATED FATTY LIVER DISEASE CLINICAL PROFILE IN LEAN PATIENTS: CAN IT BE DIFFERENT? |
title_sort |
o-23 metabolic associated fatty liver disease clinical profile in lean patients: can it be different? |
publisher |
Elsevier |
series |
Annals of Hepatology |
issn |
1665-2681 |
publishDate |
2021-09-01 |
description |
Background: The prevalence of metabolic associated fatty liver disease (MAFLD) in lean patients has grown around the world and the better understanding of this liver disease, in these individuals, has become of interest. Aim: To evaluate the profile of MAFLD in lean compared to obese patients. Methodology: This case-series included patients with MAFLD from a hepatology clinic. MAFLD criteria included the presence of steatosis (ultrasound) and one of the following clinical conditions: overweight/obesity, type 2 diabetes mellitus (T2DM), other features of metabolic dysfunction. Fibrosis was evaluated by FIB4 and APRI scores. Two groups were considered: G1-lean adult (BMI≤24.99 kg/m²); elderly (≥60 years- BMI<28 kg/m²) patients; G2-obese adult (BMI≥25kg/m²); elderly (BMI>28kg/m²). SPSS software was used for data analysis. Results: A total of 135 MAFLD patients were included: 57(42.2%) in G1; 78(57.8%) in G2. G1 characteristics: Mean age was 62.26 years (SD=11.71); 70.2% were women; 75% were of African descent (self-declared); BMI mean: 24.59kg/m²(SD=2.37). Hypertriglyceridemia (HYT) was observed in 42.9% patients, T2DM in 47.4%, arterial hypertension (AH) in 54.4%, and low HDL 41.2%. Fibrosis not observed by FIB4 or APRI in all lean cases. G2 characteristics: Mean age was 55.62 years (SD=10.4); 80.8% were women; BMI mean: 32.05kg/m² (SD=3.78); 91% were of African descent. AH was found in 57.7% of the cases; T2DM in 46.2%; HYT in 36.1% and low HDL in 38.6%. Fibrosis was not observed by FIB4 and 5.5% presented fibrosis by APRI. Conclusions: In these lean patients, MAFLD was frequent in elderly women; hypertriglyceridemia, T2DM were relevant risk factor; and they did not present fibrosis by noninvasive scores. The prevalence of Afro descent in this MAFLD population was elevated and the ethnicity influence in these cases needs to be better understood in future studies. |
url |
http://www.sciencedirect.com/science/article/pii/S166526812100209X |
work_keys_str_mv |
AT andrezarosacabral o23metabolicassociatedfattyliverdiseaseclinicalprofileinleanpatientscanitbedifferent AT anarafaelasdovale o23metabolicassociatedfattyliverdiseaseclinicalprofileinleanpatientscanitbedifferent AT naiadessalmeida o23metabolicassociatedfattyliverdiseaseclinicalprofileinleanpatientscanitbedifferent AT raquelrocha o23metabolicassociatedfattyliverdiseaseclinicalprofileinleanpatientscanitbedifferent AT antonioricardocfdeandrade o23metabolicassociatedfattyliverdiseaseclinicalprofileinleanpatientscanitbedifferent AT anacristinalandin o23metabolicassociatedfattyliverdiseaseclinicalprofileinleanpatientscanitbedifferent AT helmapcotrim o23metabolicassociatedfattyliverdiseaseclinicalprofileinleanpatientscanitbedifferent |
_version_ |
1716864867654172672 |